Silver Oak Securities Incorporated Has $956,000 Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Silver Oak Securities Incorporated raised its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 136.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,349 shares of the pharmaceutical company’s stock after purchasing an additional 1,355 shares during the period. Silver Oak Securities Incorporated’s holdings in Vertex Pharmaceuticals were worth $956,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Sherbrooke Park Advisers LLC increased its stake in Vertex Pharmaceuticals by 65.3% in the third quarter. Sherbrooke Park Advisers LLC now owns 2,645 shares of the pharmaceutical company’s stock valued at $920,000 after purchasing an additional 1,045 shares in the last quarter. Robeco Institutional Asset Management B.V. boosted its holdings in shares of Vertex Pharmaceuticals by 6.5% in the third quarter. Robeco Institutional Asset Management B.V. now owns 432,937 shares of the pharmaceutical company’s stock valued at $150,550,000 after buying an additional 26,523 shares during the period. Telos Capital Management Inc. boosted its holdings in shares of Vertex Pharmaceuticals by 1.6% in the fourth quarter. Telos Capital Management Inc. now owns 15,073 shares of the pharmaceutical company’s stock valued at $6,133,000 after buying an additional 237 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Vertex Pharmaceuticals by 1.3% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 427,001 shares of the pharmaceutical company’s stock valued at $148,485,000 after buying an additional 5,514 shares during the period. Finally, Machina Capital S.A.S. acquired a new position in shares of Vertex Pharmaceuticals in the third quarter valued at approximately $816,000. Institutional investors own 90.96% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on VRTX. Sanford C. Bernstein cut shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Friday, February 2nd. Oppenheimer reiterated an “outperform” rating and issued a $500.00 price target on shares of Vertex Pharmaceuticals in a report on Monday, April 15th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $440.00 price target on shares of Vertex Pharmaceuticals in a report on Tuesday, February 20th. Canaccord Genuity Group restated a “sell” rating and set a $371.00 target price on shares of Vertex Pharmaceuticals in a report on Friday, April 12th. Finally, Evercore ISI upgraded shares of Vertex Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $438.00 target price for the company in a report on Thursday, April 11th. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $429.45.

Vertex Pharmaceuticals Price Performance

NASDAQ:VRTX opened at $396.39 on Monday. Vertex Pharmaceuticals Incorporated has a 52 week low of $320.01 and a 52 week high of $448.40. The firm has a market cap of $102.45 billion, a price-to-earnings ratio of 28.62, a P/E/G ratio of 1.87 and a beta of 0.35. The firm’s 50-day simple moving average is $411.60 and its 200 day simple moving average is $399.17. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.78 and a current ratio of 3.99.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.85 by $0.35. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. The firm had revenue of $2.52 billion for the quarter, compared to the consensus estimate of $2.50 billion. During the same period in the prior year, the company posted $3.33 earnings per share. As a group, sell-side analysts predict that Vertex Pharmaceuticals Incorporated will post 14.95 earnings per share for the current year.

Insider Buying and Selling

In other news, EVP Ourania Tatsis sold 354 shares of Vertex Pharmaceuticals stock in a transaction on Monday, February 26th. The shares were sold at an average price of $425.70, for a total value of $150,697.80. Following the completion of the sale, the executive vice president now owns 55,804 shares in the company, valued at approximately $23,755,762.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Chairman Jeffrey M. Leiden sold 2,656 shares of the firm’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $419.51, for a total value of $1,114,218.56. Following the completion of the sale, the chairman now owns 27,644 shares of the company’s stock, valued at $11,596,934.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Ourania Tatsis sold 354 shares of the firm’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $425.70, for a total value of $150,697.80. Following the transaction, the executive vice president now owns 55,804 shares of the company’s stock, valued at $23,755,762.80. The disclosure for this sale can be found here. Insiders have sold a total of 12,381 shares of company stock worth $5,203,249 in the last ninety days. Company insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.